KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Amortization - Intangibles (2019 - 2022)

Historic Amortization - Intangibles for Royalty Pharma (RPRX) over the last 4 years, with Q1 2022 value amounting to $5.7 million.

  • Royalty Pharma's Amortization - Intangibles fell 1.76% to $5.7 million in Q1 2022 from the same period last year, while for Dec 2022 it was $5.7 million, marking a year-over-year decrease of 7534.35%. This contributed to the annual value of $5.7 million for FY2022, which is 7534.35% down from last year.
  • According to the latest figures from Q1 2022, Royalty Pharma's Amortization - Intangibles is $5.7 million, which was down 1.76% from $5.8 million recorded in Q4 2021.
  • Royalty Pharma's Amortization - Intangibles' 5-year high stood at $5.8 million during Q3 2019, with a 5-year trough of $5.7 million in Q1 2022.
  • Moreover, its 4-year median value for Amortization - Intangibles was $5.8 million (2019), whereas its average is $5.8 million.
  • Its Amortization - Intangibles has fluctuated over the past 5 years, first changed by 0.0% in 2020, then plummeted by 108.15% in 2021.
  • Royalty Pharma's Amortization - Intangibles (Quarter) stood at $5.8 million in 2019, then changed by 0.0% to $5.8 million in 2020, then changed by 0.0% to $5.8 million in 2021, then fell by 2.17% to $5.7 million in 2022.
  • Its Amortization - Intangibles was $5.7 million in Q1 2022, compared to $5.8 million in Q4 2021 and $5.8 million in Q3 2021.